My WebLink
|
Help
|
About
|
Sign Out
Home
Reso 2021-178 Settlement Agmt McKesson Corp Cardinal Health Amerisource Berfen Johnson & Johnson Janssen Pharma
CityHall
>
City Clerk
>
City Council
>
Resolutions
>
2021
>
Reso 2021-178 Settlement Agmt McKesson Corp Cardinal Health Amerisource Berfen Johnson & Johnson Janssen Pharma
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
12/21/2023 11:39:45 AM
Creation date
12/16/2021 11:18:42 AM
Metadata
Fields
Template:
CM City Clerk-City Council
CM City Clerk-City Council - Document Type
Resolution
Document Date (6)
1/21/3202
Retention
PERM
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
3
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
RESOLUTION THE CITY COUNCIL OF THE CITY OF SAN LEANDRO <br />RESOLUTION NO.2021-178 <br />RESOLUTION OF THE CITY OF SAN LEANDRO CITY COUNCIL APPROVING <br />AND AUTHORIZING THE CITY OF SAN LEANDRO TO ENTER INTO <br />SETTLEMENT AGREEMENTS WITH MCKESSON CORPORATION, CARDINAL <br />HEALTH, INC. AMERISOURCE BERGEN CORPORATION, JOHNSON & JOHNSON, <br />JANSSEN PHARMACEUTICALS, INC. ORHTO-MCNEIL-JANSSEN <br />PHARMACEUTICALS, INC., AND JANSSEN PHARMACEUTICALS, INC. TO <br />PARTICIPATE AND RECEIVE SETTLEMENT FUNDS DERIVED FROM MULTI - <br />DISTRICT LITIGATION IN COOPERATION WITH THE CALIFORNIA <br />ATTORNEY GENERAL <br />WHEREAS, the United States is facing an ongoing public health crisis of opioid abuse, <br />addiction, overdose, and death. The State of California and California local governments spend <br />millions of dollars each year to address the direct consequences of this crisis; and <br />WHEREAS, since 2017, state and local governments in California and around the United <br />States have been pursuing litigation against certain manufacturers, distributors, and retailers of <br />opioid pharmaceuticals (the "Opioid Defendants") in an effort to hold the Opioid Defendants <br />financially responsible for the impact of the Opioid Epidemic; and <br />WHEREAS, negotiations to settle claims against several of the Opioid Defendants, <br />specifically McKesson Corporation, Cardinal Health, Inc., AmerisourceBergen Corporation, <br />Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., <br />and Janssen Pharmaceutical, Inc. (the "Settling Defendants") have been ongoing for several <br />years; and <br />WHEREAS, negotiations with the Settling Defendants have resulted in proposed <br />nationwide settlements of state and local government claims to settle the litigation; and <br />WHEREAS, the proposed terms of those proposed nationwide settlements have been set <br />forth in the Distributors Master Settlement Agreement and the J&J Master Settlement Agreement <br />(collectively "Settlement Agreements"); and <br />WHEREAS, the Settlement Agreements provide, among other things, for the payment of a <br />certain sum to settling government entities in California including to the State of California upon <br />occurrence of certain events as defined in the Settlement Agreements ("California Opioid <br />Funds"); and <br />WHEREAS, California local governments have engaged in extensive discussions with <br />the California Attorney General's Office ("AGO") as to how the California Opioid Funds will be <br />allocated, which has resulted in the Proposed California State -Subdivision Agreement Regarding <br />Distribution and Use of Settlement Funds -Distributor Settlement and the Proposed California <br />State -Subdivision Agreement Regarding Distribution and Use of Settlement Funds -Janssen <br />Settlement (collectively the "Allocation Agreements,") which are agreements between all of the <br />entities identified in the Allocation Agreements; and <br />WHEREAS, the Allocation Agreements propose to allocate the California Opioid Funds <br />15% to a State Fund; 70% to local governments in an Abatement Accounts Fund; and 15% to <br />litigating local governments in a Subdivision Fund. For the avoidance of doubt, all funds <br />
The URL can be used to link to this page
Your browser does not support the video tag.